Research programme: obesity therapy - MigenixAlternative Names: MITO-3108; MX-3108
Latest Information Update: 06 Jun 2007
At a glance
- Originator MIGENIX
- Mechanism of Action Methylmalonyl CoA mutase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Apr 2006 Discontinued - Preclinical for Obesity in USA (Parenteral)
- 18 Apr 2006 This programme is still in active development
- 25 May 2005 Preclinical trials in Obesity in USA (unspecified route)